During a routine immunization clinic in an urban slum in Delhi, a 14-month-old girl is brought for her second MMR dose (first dose given at 9 months). The child's mother reports that 2 weeks ago, the child developed bilateral parotid swelling, low-grade fever (37.8°C), and mild difficulty in chewing. The swelling resolved within 5 days without treatment. Today, the child appears healthy with no parotitis. The immunization nurse is unsure whether to give the MMR dose now or delay it. What is the most appropriate action, and what is the epidemiological significance of this presentation?

Explanation

## Clinical Scenario Analysis ### Diagnosis of Recent Mumps Infection **Key Point:** Bilateral parotid swelling with low-grade fever and difficulty chewing in a partially vaccinated child, resolving spontaneously within 5 days, is classic for **mumps** (paramyxovirus). This child almost certainly had a natural mumps infection 2 weeks ago. **Clinical Pearl:** Mumps typically causes: - Bilateral parotid swelling (70% of cases; can be unilateral) - Fever 38–39°C, malaise, anorexia, difficulty eating/drinking - Resolution in 3–7 days - Complications: meningitis (1–10%), orchitis (20–30% in post-pubertal males), pancreatitis, sensorineural deafness (rare) ### Immunization Decision: Administer MMR Now **High-Yield:** The child has **natural mumps immunity** from the recent infection, which is typically **lifelong (>95% protection)**. Administering MMR now is still appropriate because: 1. **No contraindication** exists to giving MMR after a recent natural viral infection — unlike two live vaccines given simultaneously or within 4 weeks of each other, a natural infection does not interfere with subsequent MMR vaccine take. 2. The MMR vaccine will provide additional protection against **measles and rubella**, for which the child remains susceptible (one dose at 9 months gives only ~78–88% protection against measles). 3. The combination of natural mumps immunity + MMR vaccination creates **hybrid immunity**, which is immunologically superior to vaccine-induced immunity alone and provides more durable, broader protection. **Why Option A is incorrect:** Option A states the child "is not immune" — this is factually wrong. The child *is* immune to mumps from natural infection. The correct rationale for giving MMR now is hybrid immunity, not absence of immunity. **Why Delay is NOT Appropriate (Options B and D):** There is no standard recommendation to delay MMR after natural mumps infection. A 3-month or 6-month delay is not supported by IAP, WHO, or CDC guidelines. Delaying would leave the child unprotected against measles and rubella unnecessarily. ### Epidemiological Significance | Aspect | Detail | | --- | --- | | **First dose MMR efficacy (measles)** | ~85–95% (given at 9 months, lower due to maternal antibodies) | | **Two-dose MMR efficacy (mumps)** | ~95–98% | | **Natural mumps immunity** | Lifelong (>95% protection) | | **Hybrid immunity** | Natural infection + vaccine = superior, durable protection | | **Vaccine failure** | Breakthrough mumps after 1 MMR dose highlights need for 2-dose schedule | **High-Yield:** This child represents a **single-dose vaccine failure** — breakthrough mumps despite one MMR dose at 9 months. This is epidemiologically significant because: - It underscores the importance of the **2-dose MMR schedule** (9 months + 15–18 months per IAP; 12–15 months + 4–6 years per CDC) - Single-dose coverage is insufficient for herd immunity against mumps - In urban slums with suboptimal vaccination coverage, mumps outbreaks occur even in partially vaccinated populations **Clinical Pearl:** Administering MMR now is safe, beneficial, and creates hybrid immunity — the most protective state against mumps, while also completing measles and rubella coverage. [cite: Park's Textbook of Preventive & Social Medicine, 26th ed., Ch. 8; IAP Immunization Guidelines 2023; CDC Pink Book — Mumps]